Welcome to







. , .pdf-, . . , . , , . e-mail. , , . , : (495) 730-63-51 e-mail: atm-press2012@yandex.ru



-




  

2021 / N 4

COVID-19
..


References

1. Tsai ST, Lu MK, San S, Tsai CH. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Frontiers in Neurology 2020 May;11:498.
2. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021 Jan;397(10270):220-32.
3. Boesl F, Audebert H, Endres M, Prüss H, Franke C. A neurological outpatient clinic for patients with post-COVID-19 syndrome a report on the clinical presentations of the first 100 patients. Frontiers in Neurology 2021 Sep;12:738405.
4. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thålin C. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021 May;325(19):2015-6.
5. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet. Psychiatry 2021 May;8(5):416-27.
6. Fearon C, Fasano . Parkinsons disease and the COVID-19 pandemic. Journal of Parkinsons Disease 2021;11(2):431-44.
7. Beauchamp LC, Finkelstein DI, Bush AI, Evans AH, Barnham KJ. Parkinsonism as a third wave of the COVID-19 pandemic? Journal of Parkinsons Disease 2020;10(4):1343-53.
8. Alipoor SD, Mortaz E, Varahram M, Garssen J, Adcock IM. The immunopathogenesis of neuroinvasive lesions of SARS-CoV-2 infection in COVID-19 patients. Frontiers in Neurology 2021 Jul;12:697079.
9. Sharma S, Jagadeesh H, Saxena A, Chakravarthy H, Devanathan V. Central nervous system as a target of novel coronavirus infections: potential routes of entry and pathogenic mechanisms. Journal of Biosciences 2021;46(4):106.
10. Lippi A, Domingoes R, Setz C, Outeiro TF, Krisko A. SARS-CoV2: at the crossroad between aging and neurodegeneration. Movement Disorders 2020 May;35(5):716-20.
11. Brundin P, Nath A, Beckman JD. Is COVID-19 a perfect storm for Parkinsons disease? Trends in Neurosciences 2020 Dec;43(12):931-3.
12. Artusi CA, Romagnolo A, Ledda C, Zibetti M, Rizzone MG, Montanaro E, Bozzali M, Lopiano L. COVID-19 and Parkinsons disease: what do we know so far? Journal of Parkinsons Disease 2021;11(2):445-54.
13. Silva-Batista C, Coelho DB, Freire Júnior RC, Almeida LR, Guimarães A, Nóbrega KCC, Sanchez HM, Lindquist AR, Israel VL, Kanegusuku H, Guimarães R, Beckmann Bosaipo N, Barbosa R, Correa CL, Finatto MJ, Dos Santos Mendes FA, Pimentel Piemonte ME. Multidimensional factors can explain the clinical worsening in people with Parkinsons disease during the COVID-19 pandemic: a multicenter cross-sectional trial. Frontiers in Neurology 2021 Jul;12:708433.
14. Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental health, physical activity and quality of life in Parkinsons disease during COVID-19 pandemic. Movement Disorders 2020 Jul;35(7):1097-9.
15. Brugger F, Erro R, Balint B, Kägi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinsons disease during systemic infections a hypothetical view. NPJ Parkinsons Disease 2015 Aug;1:15014.
16. Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM, Devigili G, Cereda E, Eleopra R. Effects of COVID-19 on Parkinsons disease clinical features: a community-based case-control study. Movement Disorders 2020;35:1287-92.
17. Fishman PS, Gass JS, Swoveland PT, Lavi E, Highkin MK, Weiss SR. Infection of the basal ganglia by a murine coronavirus. Science 1985 Aug;229(4716):877-9.
18. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinsons disease. Movement Disorders 1992;7(2):153-8.
19. Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DHT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz R, Chen S. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 2020 Jul;27(1):125-136.e7.
20. Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY. COVID-19 and Parkinsons disease: shared inflammatory pathways under oxidative stress. Brain Sciences 2020 Oct;10(11):807.
21. Rodriguez-Perez AI, Garrido-Gil P, Pedrosa MA, Garcia-Garrote M, Valenzuela R, Navarro G, Franco R, Labandeira-Garcia JL. Angiotensin type 2 receptors: role in aging and neuroinflammation in the substantia nigra. Brain, Behavior and Immunity 2020 Jul;87:256-71.
22. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, OMeara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards SL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu YF, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, ONeal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten D, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, dEnfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020 Jul;583(7816):459-68.
23. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, Paul JJ, Gaber H, Skrahina V, Bornstein NM, Yahalom G. A case of probable Parkinsons disease after SARS-CoV-2 infection. The Lancet. Neurology 2020 Oct;19(10):804-5.
24. Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Movement Disorders 2020 Oct;35(10):1721-2.
25. Méndez-Guerrero, Laespada-García MI, Gómez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, Rábano-Suárez P, Álvarez-Torres E, de Fuenmayor-Fernández de la Hoz CP, Pérez DV, Rodríguez-Montalbán R, Pérez-Rivilla A, Catalán JS, Ramos-González A, González de la Aleja J. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 2020 Oct;95(15):e2109-18.
26. Brison E, Jacomy H, Desforges M, Talbot PJ. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. Journal of Virology 2014 Feb;88(3):1548-63.
27. Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D. Parkinsons disease the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. Journal of Parkinsons Disease 2013;3(1):1-11.
28. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nature Reviews Disease Primers 2017 Mar;3:17013.
29. Hornykiewicz O. L-DOPA. Journal of Parkinsons Disease 2017;7(Suppl 1):S3-10.
30. Guidelines for diagnosis and treatment of Parkinsons disease. Illarioshkin SN, Levin OS, editors. Moscow: MEDpress-Inform; 2016. 336 p. (In Russian).
31. Illarioshkin SN, Fedotova EYu, Seliverstov YuA. Current high-tech methods of treatment of Parkinsons disease. In: Brain diseases: medical and social aspects. Gusev EI, Gekht AB, editors. Moscow: Buki-Vedi; 2016: 543-52 (In Russian).
32. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinsons disease. Advances in Neurology 1996;69:497-501.
33. Poleshchuk VV, Illarioshkin SN. Amantadine in Parkinsons disease: modern possibilities of long-term therapy. Medical Council 2018;9:34-8 (In Russian).
34. Cersósimo MG, Micheli FE. Antiglutamatergic drugs in the treatment of Parkinsons disease. In: Handbook of clinical neurology. Vol. 84. Parkinsons disease and related disorders. Part II. Koller C, Melamed E, editors. New York: Elsevier; 2007: 127-36.
35. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications. Clinical Neurology and Neurosurgery 1992;94( Suppl):S4-6.
36. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995 Jul;34(7);713-21.
37. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinsons disease. A double blind, placebo controlled, crossover study with long term follow up. Neurology 1975 Jul;25(7):603-6.
38. Fahn S, Isgreen WP. Long term evaluation of amantadine and levodopa combination in parkinsonism by double blind crossover analysis. Neurology 1975 Aug;25(8):695-700.
39. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinsons disease. Diseases of Nervous System 1977 Aug;38(8):605-8.
40. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinsons disease. CNS Drugs 2007;21(8):677-92.
41. Da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, Sales De Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism & Related Disorders 2005 Nov;11(7):449-52.
42. Luginger E, Wenning GK, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinsons disease. Movement Disorders 2000 Sep;15(5):873-8.
43. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Movement Disorders 1998 Sep;13(5):851-4.
44. Růzicka E, Streitová H, Jech R, Kanovský P, Roth J, Rektorová I, Mecír P, Hortová H, Bares M, Hejduková B, Rektor I. Amantadine infusion treatment of motor fluctuations and dyskinesias in Parkinsons disease. Journal of Neural Transmission (Vienna, Austria: 1996) 2000;107(11):1297-306.
45. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders 2001 May;16(3):515-20.
46. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinsons disease. Movement Disorders 2010 Jul;25(10):1357-63.
47. Elahi B, Phielipp N, Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. The Canadian Journal of Neurological Sciences 2012 Jul;39(4):465-72.
48. Ilzenberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi C, Rossi C, Klein C, Rabey JM. Association between amantadine and the onset of dementia in Parkinsons disease. Movement Disorders 2006 Sep;21(9):1375-9.
49. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment as an independent predictor of improved survival in Parkinsons disease. Neurology 1996 Jun;46(6):1551-2.
50. Levin OS, Fedorova NV. Parkinsons disease. 4th ed. Moscow: MEDpress-inform; 2014. 384 p. (In Russian).
51. Onofri M, Thomas A. Acute akinesia in Parkinsons disease. Neurology 2005 Apr;64(7):1162-9.
52. Levin OS. Phenomenology and treatment of Parkinsons disease decompensation. Neurological Journal 2007;1:8-15 (In Russian).
53. Pielak RM, Chou JJ. Influenza M2 proton channels. Biochimica et Biophysica Acta 2011 Feb;1808(2):522-9.
54. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinsons disease. JAMA 1969 May;208(7):1168-70.
55. Araujo R, Aranda-Martinez JD, Aranda-Abreu GE. Amantadine treatment for people with COVID-19. Archives of Medical Research 2020 Oct;51(7):739-40.
56. Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. Journal of Medical Virology 2020 Nov;92(11):2341-2.
57. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R. Use of amantadine in a patient with SARS-CoV-2. Journal of Medical Virology 2021 Jan;93(1):110-11.
58. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders 2020 Jul;42:102163.
59. Cortés Borra A. Does amantadine have a protective effect against COVID-19? Neurologia i Neurochirurgia Polska 2020;54(3):284-5.
60. Tipton PW, Wszolek ZK. What can Parkinsons disease teach us about COVID-19? Neurologia i Neurochirurgia Polska 2020;54(2):204-6.
61. Brenner SR, Butterworth RF. Repurposing of adamantanes with transmitter receptor antagonist properties for the prevention/treatment of COVID-19. Journal of Pharmaceutics & Pharmacology 2020 Jan;8(1):4.
62. Butterworth RF. Potential for the repurposing of adamantane antivirals for COVID-19. Drugs in R&D 2021 Sep;21(3):267-72.
63. Aranda-Abreu GE, Hernández Aguilar ME, Herrera Covarrubias D, Rojas Durán F. Amantadine as a drug to mitigate the effects of COVID-19. Medical Hypotheses 2020 Jul;140:109755.
64. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. International Journal of Antimicrobial Agents 2020 Jun;55(6):106004.
65. Torres J, Mahswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Science 2007 Sep;16(9):2065-71.
66. Cimolai N. Potentially repurposing adamantanes for COVID-19. Journal of Medical Virology 2020 Jun;92(6):531-2.
  

[ N 4 | | ]